ClinicalTrials.gg
CompletedNCT01080079Updated Oct 19, 2012

Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis

A Phase 2 interventional study of Terbinafine Hydrochloride and Purified Water in Onychomycosis, sponsored by Nitric BioTherapeutics, Inc. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-19.

Sponsored by Nitric BioTherapeutics, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.

Enrollment
9th of 19
168 · median 100
Started
2010
with 1 other
Phase 2
5 of 20
1 open now
Registered
7th of 20
by date
Lead sponsor
2 of 20
Nitric BioTherapeutics, Inc

Among the 20 studies testing terbinafine in Onychomycosis, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2010, is one of 5 in phase 2, and was the 7th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:

About terbinafine

Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing terbinafine in Onychomycosis, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the iontophoretic application of terbinafine gel is safe and effective for teh treatment of distal subungual onychomycosis

03

Conditions studied

  • Onychomycosis

Browse trials for

Keywords

  • Onychomycosis
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Positive clinical findings for distal subungual onychomycosis as determined by clinical examination
  • Must have a great toenail involvement with onychomycosis in ≥25-≤65% of the visible nail. (more than one nail maybe affected however only the index great toenail will be evaluated)
  • Nail plate must be ≤ 3 mm thick.
  • Must have a positive KOH and positive identification of a Dermatophyte via culture.
  • Written must be obtained from the subject.
  • Must be ≥ 18 and \< 70 years of age, unless local laws dictate otherwise.
  • Must agree to avoid any type of pedicure or application of any nail polish product or nail cosmetic to the toenails after the screening visit until the conclusion of the trial.
  • Must agree to take measures to avoid pregnancy during the study period
  • Must agree to avoid the use of oral or topical antifungals unless provided by the investigator for the relief of symptomatic (active clinical signs) tinea pedis which has occurred during the treatment / follow up phase of the study. (The treatment provided will be Lotrimin®).

Exclusion criteria

Exclusion Criteria:

    • The presence of proximal subungual onychomycosis or white superficial onychomycosis
  • Fungal involvement of the lunula or less than 2 mm of clear nail from the the proximal nail fold
  • Subjects with psoriasis, eczema, symptomatic (with active clinical signs) interdigital or plantar tinea pedis, lichen planus, or other abnormalities (e.g. traumatized or dystrophic nails) that could result in a clinically abnormal nail or the investigator thinks the current condition will compromise the integrity of the trial
  • Any presence of dermatophytoma or onychomycotic spikes
  • Subjects with either uncontrolled diabetes mellitus or known diabetics on pharmaceutical therapy or those with no palpable pedal pulse
  • Subjects with peripheral vascular disease
  • Subjects who are - those on chronic therapy (see below), with solid organ or bone marrow transplantation, cytotoxic chemotherapy within the previous 12 months (or planned within the next 12 months), or infection.
  • Use of topical antifungals e.g. (clotrimazole, ketoconazole, miconazole, oxiconazole (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole, econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, tolnaftate, haloprogin), Zeasorb-AF Ciclopirox (e.g. Penlac® Nail Lacquer, Sanofi-Aventis) and corticosteroids (e.g. hydrocortisone, betamethasone, fluticasone and mometasone) in the preceding 15 days of Day 1, on or immediately around the area under evaluation.
  • Use of systemic corticosteroids within 30 days preceding Day 1
  • Use of systemic antifungals in the preceding 120 days of Day 1 including - (terbinafine - (Lamisil®, Novartis), Itraconazole - (Sporanox®, Janssen), fluconazole- (Diflucan®, Pfizer), ketoconazole, miconazole, griseofulvin (Gris-PEG®, Pedinol), butoconazole, terconazole, potassium iodide,.
  • Has used any drug(s) within 30 days preceding Day 1, with the exception of investigational systemic antifungals (120 days))
  • Is pregnant or is a nursing mother
  • Is a woman of child bearing potential who is not using an adequate form of (or abstinence)
  • Is \< 18 years of age, unless local laws dictate otherwise.
  • Suffers from a condition, which, in the opinion of the medical investigator, would compromise his/her safety and / or the quality of the data.
  • Subjects with a pacemaker or automatic implantable cardioverter/defibrillator.
  • Subjects with an implantable electronic device.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
168 participants (actual)

Study arms

  • Active comparator
    Group A -Terbinafine HCl

    Terbinafine HCl

    Drug: Terbinafine Hydrochloride

  • Active comparator
    Group B - Terbinafine HCl

    Terbinafine HCl

    Drug: Terbinafine Hydrochloride

  • Active comparator
    Group C - Terbinafine HCl

    Terbinafine HCl

    Drug: Terbinafine Hydrochloride

  • Active comparator
    Group D Terbinafine HCl

    Terbinafine HCl

    Drug: Terbinafine Hydrochloride

  • Active comparator
    Group E

    Terbinafine HCl

    Drug: Terbinafine Hydrochloride

  • Placebo comparator
    Group F - Placebo

    Placebo application

    Other: Purified Water

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical and Microbiological Improvement in nails vs placebo

    Time frame: 11 months

07

Study locations

9 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • International Clinical Research, LLC
    Sanford, Florida 32771, United States
  • Gwinnett Clinical Research Center, Inc
    Snellville, Georgia 30078, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Temple University Schoool of Podiatric Medicine
    Philadelphia, Pennsylvania 19107, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Endeavor Clinical Trials, PA
    San Antonio, Texas 78229, United States
  • Mediprobe Research, Inc
    London, Ontario N5X 2P1, Canada
  • Lynderm Research, Inc
    Markham, Ontario L3P 1A8, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Nov 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2010
First posted
Mar 3, 2010
Start
May 2010
Primary completionActual
Nov 2011
CompletionActual
Jun 2012
Last update
Oct 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01080079
Lead sponsor
Nitric BioTherapeutics, Inc
Responsible party
Sponsor
First posted
Mar 3, 2010
Start date
May 2010
Primary completion
Nov 2011
Completion
Jun 2012
Last update
Oct 19, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion